These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19839928)

  • 1. Predictive markers for haematological toxicity of pemetrexed.
    Kao SC; Phan VH; Clarke SJ
    Curr Drug Targets; 2010 Jan; 11(1):48-57. PubMed ID: 19839928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed safety and dosing strategy.
    Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
    Li KM; Rivory LP; Clarke SJ
    Br J Cancer; 2007 Oct; 97(8):1071-6. PubMed ID: 17912246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical pharmacology of pemetrexed.
    Calvert AH
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):13-7. PubMed ID: 15655931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
    Niyikiza C; Baker SD; Seitz DE; Walling JM; Nelson K; Rusthoven JJ; Stabler SP; Paoletti P; Calvert AH; Allen RH
    Mol Cancer Ther; 2002 May; 1(7):545-52. PubMed ID: 12479273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate status and the safety profile of antifolates.
    Calvert H
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):3-7. PubMed ID: 12023786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
    Chattopadhyay S; Tamari R; Min SH; Zhao R; Tsai E; Goldman ID
    Oncologist; 2007 Jul; 12(7):808-15. PubMed ID: 17673612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
    Joerger M; Omlin A; Cerny T; Früh M
    Curr Drug Targets; 2010 Jan; 11(1):37-47. PubMed ID: 19839929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
    Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M; Calvert H
    J Clin Oncol; 2002 Aug; 20(16):3533-44. PubMed ID: 12177114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
    Giovannetti E; Honeywell R; Hanauske AR; Tekle C; Kuenen B; Sigmond J; Giaccone G; Peters GJ
    Curr Drug Targets; 2010 Jan; 11(1):12-28. PubMed ID: 19839931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol.
    Kreuter M; Vansteenkiste J; Griesinger F; Hoffmann H; Dienemann H; De Leyn P; Thomas M
    BMC Cancer; 2007 May; 7():77. PubMed ID: 17488518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
    Hanauske AR; Chen V; Paoletti P; Niyikiza C
    Oncologist; 2001; 6(4):363-73. PubMed ID: 11524555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
    Solomon B; Bunn PA
    Future Oncol; 2005 Dec; 1(6):733-46. PubMed ID: 16556051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.